Tryp is pursuing chronic pain and other indications to address the significant needs of patients. Because of the relatively high prevalence of these diseases, the market opportunity for the successful development and commercialization of our treatments is enormous.
Diagnosed Prevalence in the U.S.
Peak Annual Worldwide Sales Potential for Tryp
Source: Tryp Therapeutics Projections
See how our stock is trading.
Gain visibility into the trading activity of our shares with key performance indicators and historic data.
Tryp Therapeutics Inc. is followed by the analyst listed above. To the best of Tryp Therapeutics Inc.'s knowledge, the above list reflects all firms and analysts that publish research on Tryp Therapeutics Inc. and they have agreed to have their names included on the list above. Please note that any opinions, estimates or forecasts regarding Tryp Therapeutics Inc.’s performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of Tryp Therapeutics Inc. or its management. Tryp Therapeutics Inc. does not by its reference imply its endorsement of or concurrence with such information, conclusions or recommendations.
Read our latest breakthroughs.
Learn more about our news and stay up to date on industry trends.
H.C. Wainwright Annual Psychedelics Hybrid Conference
JP Morgan Healthcare Conference
Get the latest information for investors.
Download our complete investor pack
Read the latest version of our investor deck, which includes information on our progress to date and our upcoming clinical activities.
Gain a deeper understanding of our pipeline and products.
Frequently asked questions
Get answers to common questions about Tryp, our clinical trials, commercialization and more.
Learn more about the promise of psychedelics for chronic pain and other indications.